Latest News

In its latest quarter, First Interstate BancSystem reported earnings per share ahead of analyst expectations but revenue below forecasts, alongside improving net interest margin and lower non‑performing assets. The company also expanded its share repurchase authorization, signaling management’s confidence in its capital position and balance sheet resilience. Next, we’ll examine how the expanded share repurchase authorization may influence First Interstate BancSystem’s broader investment...

Janus Henderson Group (NYSE:JHG) is back on investor screens after a recent move in its share price, with the stock closing at $50.43. This has prompted a closer look at its recent return profile. See our latest analysis for Janus Henderson Group. The recent pullback, with a 1-day share price return of a 1.83% decline, comes after a steadier backdrop that includes a 90-day share price return of 6.28% and a 1-year total shareholder return of 39.00%. This suggests that momentum has been...

Marqeta (MQ) is drawing attention after recent trading left the stock at US$4.08, with a 1 day return of 3.8% and mixed performance over the month and the past 3 months. See our latest analysis for Marqeta. That 3.8% 1 day share price return comes after a weaker run, with the 30 day share price return of 3.8% and the year to date share price return of 12.1% both well behind the 3 year total shareholder return of 14.3%. This suggests recent momentum has faded even though longer term holders...

Wondering whether GeneDx Holdings at around US$69.84 is a bargain or already pricing in a lot of optimism? This article walks through what the numbers currently say about value. The stock has had a choppy run, with a 10.2% decline over the last 7 days, a 14.9% decline over the last 30 days, a 47.2% decline year to date, a very large 3 year return, and a 33.1% decline over the last year. These swings have kept GeneDx on the radar for investors watching for changing expectations and risk...

Okuma (TSE:6103) has attracted fresh attention after recent share price moves, with the stock showing a 5% decline over the past week and a 16% decline over the past month. See our latest analysis for Okuma. Despite the recent 15.8% 30 day share price decline to ¥3,820, Okuma still shows firmer longer term momentum, with a 90 day share price return of 8.7% and a 1 year total shareholder return of 9.0%, highlighting a stronger multi year record. If this recent pullback has you reassessing your...

XXF Group Holdings (SEHK:2473) has opened FY 2025 with first half revenue of C¥613.1 million and basic EPS of C¥0.014536, while the trailing 12 month line shows revenue of about C¥1.3 billion and EPS of C¥0.027649. Over the last three reported half years, revenue has moved from C¥504.3 million in 1H FY 2024 to C¥661.3 million in 2H FY 2024 and then C¥613.1 million in 1H FY 2025, with EPS stepping from C¥0.012725 to C¥0.013113 and most recently C¥0.014536. This sets up an earnings story where...

Wondering whether CRISPR Therapeutics at around US$46.24 is offering good value, or if the recent excitement is already priced in? This breakdown is designed to help you frame that question clearly. The stock is up 12.2% over the past year, even though it shows a 5.1% decline over 7 days, a 13.5% decline over 30 days, and a 14.0% decline year to date. Recent trading has therefore looked quite different to the longer term picture. Recent headlines around CRISPR Therapeutics have focused on...

Hermès International has filed its 2025 Universal Registration Document with the French Financial Markets Authority, making its latest annual activity report, consolidated financial statements, sustainability information, and share buyback programme details available to the public. This comprehensive filing gives investors a single source to review Hermès’ financial position, non-financial commitments, and capital allocation approach, including how buybacks fit alongside its long-term brand...

Reply (BIT:REY) has drawn investor attention after a prolonged share price slide, with the stock down over 50% in the past year and around 32% over the past 3 months. See our latest analysis for Reply. The recent 1 day share price return of a 3.1% decline and 7 day share price return of a 9.6% decline add to a 1 year total shareholder return of a 51.3% decline, pointing to fading momentum and a reassessment of risk around Reply, despite its €78.75 share price and existing growth initiatives...

Alvopetro Energy (TSXV:ALV) is back on investors’ radar after reporting full year 2025 results, with revenue of US$55.89 million and net income of US$23.1 million, alongside declaring a quarterly cash dividend. See our latest analysis for Alvopetro Energy. At a share price of CA$8.73, Alvopetro’s 35.14% 3 month share price return and 94.49% 1 year total shareholder return suggest that momentum has been building around its earnings growth and dividend announcement. If this mix of earnings...

Nike (NYSE:NKE) is reporting early signs of a turnaround as wholesale revenue shows a rebound. Management is working to repair relationships with wholesale partners, with recent updates pointing to more stable sales trends. These shifts come while consumer demand and broader macroeconomic conditions remain under pressure. Nike operates at the center of global athletic footwear and apparel, where brand reach and product relevance are crucial. Recent weakness in demand, profit headwinds, and...

Earnings event puts WELL Health Technologies in focus WELL Health Technologies (TSX:WELL) moved into the spotlight after reporting full year 2025 results that combined revenue growth and clinic expansion with a shift to a net loss and new 2026 guidance. See our latest analysis for WELL Health Technologies. The earnings release and 2026 guidance came alongside a sharp 1 day share price return of negative 10.02%, extending a weaker trend that includes a 30 day share price return of negative...

Deepexi Technology (SEHK:1384) has reported fresh numbers for FY 2025, with first half revenue of C¥132.1 million and a basic EPS loss of C¥1.12, while the trailing twelve months show revenue of C¥314.5 million and a basic EPS loss of C¥3.92. The company’s revenue moved from C¥129.0 million in 2H 2023 to C¥242.9 million in 2H 2024 and then to C¥132.1 million in 1H 2025. Net income excluding extra items shifted from a loss of C¥502.9 million in 2H 2023 to a loss of C¥1.25 billion in 2H 2024...

Event context and recent share performance Merit Medical Systems (MMSI) shares have come under pressure recently, with the stock showing a 2.4% decline over the past day, 4.6% over the past week, and deeper pullbacks over the past month and past 3 months. See our latest analysis for Merit Medical Systems. The recent pullback, including a 30 day share price return of 18.9% decline and a year to date share price return of 22.8% decline, sits alongside a 1 year total shareholder return of 34.4%...

AptarGroup's Unidose Powder Nasal Spray System is being used in ENA Respiratory's Phase II trial for INNA-051. The trial targets prevention of symptomatic viral respiratory infections through a non-vaccine nasal approach. This use case highlights AptarGroup's role in advanced nasal drug delivery technologies within clinical pipelines. AptarGroup (NYSE:ATR) is widely known for drug delivery and consumer dispensing solutions, and this latest trial involvement puts its nasal systems in the...

MDU Resources Group (MDU) has drawn attention after recent trading, with the share price around $19.65 and mixed short term returns, including a 3.7% one day decline and 6.9% drop over the past week. See our latest analysis for MDU Resources Group. That recent 1-day share price return of negative 3.7% and 7-day return of negative 6.9% sit against a much stronger backdrop, with 1-year total shareholder return of 20.8% and 3-year total shareholder return of 93.6%. This suggests long term...

Iovance Biotherapeutics (IOVA) recently outlined its growth plans at the Barclays 28th Annual Global Healthcare Conference, spotlighting early sarcoma data, broader lung and sarcoma ambitions, and upcoming Amtagvi melanoma regulatory decisions in the UK and Australia. See our latest analysis for Iovance Biotherapeutics. At a share price of $3.69, Iovance has given investors a 30 day share price return of 28.57% and a year to date share price return of 46.43%. However, the 5 year total...

Orla Mining Ltd. recently reported audited 2025 results showing quarterly gold production of 95,405 ounces, full-year output of 300,620 ounces, and sales of US$1,057.88 million alongside new 2026 production guidance. At the same time, the company secured full environmental approval for expanded open-pit mining and underground exploration at Camino Rojo in Mexico, clearing a regulatory hurdle that could reshape its long-term mine plan. We’ll now examine how Camino Rojo’s newly approved...

Carvana stock moves after recent performance shift Carvana (CVNA) has drawn fresh attention after a recent pullback, with the share price down about 16% over the past month and roughly 35% over the past 3 months. See our latest analysis for Carvana. While the share price has given back ground recently, with a 1-day share price return decline of 4.39% and a 30-day share price return decline of 16.44%, the 1-year total shareholder return of 47.31% and very large 3-year total shareholder return...

What Tencent's Recent Returns Suggest About Its Valuation Tencent Holdings can be tricky to pin down, and if you are wondering whether the current share price still offers value, it helps to line up the recent returns against what the business might be worth. Over the past week the stock recorded a 7.2% decline. The 30 day return sits at a 4.7% decline and the year to date return is an 18.5% decline. Yet the 1 year return is 0.2% and the 3 year return is 38.1%, compared with an 8.2% decline...

Travere Therapeutics (TVTX) has drawn investor attention after recent trading left the shares with a loss of 32.1% year to date, despite a 30.7% total return over the past year. See our latest analysis for Travere Therapeutics. The current share price of US$26.84 sits well below its recent peak, with a 30 day share price return of an 8.4% decline and a year to date share price return of a 32.1% decline. At the same time, the 1 year total shareholder return is 30.7%, suggesting that earlier...

Hadrian and the U.S. Navy have agreed to work together to increase production of submarine parts. The partnership is aimed at supporting U.S. naval shipbuilding capacity and easing supply chain constraints. The move has potential implications for major submarine contractors, including General Dynamics (NYSE:GD). For investors watching General Dynamics at a current share price of $345.78, this new U.S. Navy and Hadrian partnership sits directly in the orbit of the company’s core submarine...

Apollo Global Management (APO) has been in focus after Apollo managed funds agreed to invest US$1.0 billion alongside Realty Income in a joint venture owning roughly 500 single-tenant, long-lease retail properties. See our latest analysis for Apollo Global Management. At a share price of US$112.0, Apollo’s recent 7 day share price return of 7.24% has come after a 90 day share price decline of 24.78%, while its 5 year total shareholder return of 166.66% points to strong longer term...

Alumis reported full-year 2025 results showing US$24.05 million in revenue and a net loss of US$243.33 million, while also filing a universal shelf registration and a US$300 million at-the-market follow-on equity offering alongside positive Phase 3 topline data for its TYK2 inhibitor envudeucitinib in plaque psoriasis. By pairing encouraging late-stage clinical data and plans for a 2026 New Drug Application with expanded financing flexibility, Alumis is signaling a push to advance...